ProKidney

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ProKidney and other ETFs, options, and stocks.

About PROK

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. 

CEO
Bruce Culleton
CEOBruce Culleton
Employees
231
Employees231
Headquarters
Winston-Salem, North Carolina
HeadquartersWinston-Salem, North Carolina
Founded
2015
Founded2015
Employees
231
Employees231

PROK Key Statistics

Market cap
501.29M
Market cap501.29M
Price-Earnings ratio
-3.32
Price-Earnings ratio-3.32
Dividend yield
Dividend yield
Average volume
757.96K
Average volume757.96K
High today
$1.73
High today$1.73
Low today
$1.59
Low today$1.59
Open price
$1.72
Open price$1.72
Volume
635.76K
Volume635.76K
52 Week high
$7.13
52 Week high$7.13
52 Week low
$0.54
52 Week low$0.54

Stock Snapshot

As of today, ProKidney(PROK) shares are valued at $1.66. The company's market cap stands at 501.29M, with a P/E ratio of -3.32.

As of 2026-05-15, ProKidney(PROK) stock has fluctuated between $1.59 and $1.73. The current price stands at $1.66, placing the stock +4.4% above today's low and -4.0% off the high.

ProKidney(PROK) shares are trading with a volume of 635.76K, against a daily average of 757.96K.

During the past year, ProKidney(PROK) stock moved between $0.54 at its lowest and $7.13 at its peak.

During the past year, ProKidney(PROK) stock moved between $0.54 at its lowest and $7.13 at its peak.

PROK News

TipRanks 22m
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 39m
ProKidney reports Q1 EPS (14c), consensus (14c)

Reports Q1 revenue $226,000, consensus $100,250.”As we progress through 2026, we continue to build on the momentum established last year through positive Phase...

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
28.6%
Sell
14.3%

People also own

Based on the portfolios of people who own PROK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.